Log in

Log in

Introduction to Cannabis as a Treatment for Psychological Disease

  • 05 Nov 2021
  • 10:00 AM - 1:00 PM
  • Virtual


  • Participants will receive 3 CE credits.
  • This webinar is discounted for DCPA students. Please use your student email to register. Continuing education credits are not issued under this category.
  • Continuing education credits are not issued under this category.
  • Registrants will receive 3 continuing education credits.
  • Please use your student email to register. Continuing education credits are not issued under this category.
  • 3 CE credit hours will be issued under this registration.
  • 3 CE credit hours will be issued under this regisgration

Registration is closed

Event Description: 

Cannabis has been used as a medicine for thousands of years for the treatment of a bevy of neurological and mental health conditions. This presentation will discuss the benefits of medical-cannabis and provide guidance to healthcare professionals interested in exploring the possibility of recommending medical cannabis to their patients with the appropriate qualifying conditions. Dr. Lehfeldt will share the latest research on the beneficial effects of cannabis and its ability to treat a range of neuropsychiatric conditions in an effort to better understand medical cannabis, its applications, and its safety. Dr. Lehfeldt will review treatment modalities and future pharmacological topics, while also discussing the limitations of research in the cannabis sphere.

3 Continuing Education Credits are available

Learning Objectives:

Participants will be able to:

 1) Learn the history of cannabis, including the prohibition of cannabis in America which lead to federal illegality.  

2) Learn about the physiology of cannabis including retrograde neurotransmission in the endocannabinoid system and how it differs from canonical neurotransmission.

3) Explain the different mechanisms of delivery of cannabis-based medicine, learn basic pharmacokinetics including the bioavailability of different phytocannabinoids and the onset of action and duration of different cannabis formulations.

4)  Discuss the psychiatric qualifying conditions with a focus on current research on phytocannabinoids and pain, PTSD, anxiety, and psychosis.

Presenter Information:  Paloma  L. Lehfeldt, MD, MA

Dr. Paloma Lehfeldt, MD, MA, is a lifelong cannabis student and advocate who serves as the Senior Director of Clinical Science and Partnerships for Goodness Growth Holdings. Dr. Lehfeldt brings to Goodness Growth more than ten years of experience in psychiatric research, community outreach, and teaching. She has expertise in neuroscience with a keen interest in mental health and the endocannabinoid system.

At Goodness Growth, Dr. Lehfeldt is the direct line of communication with providers and organizes outreach events, conferences, continuing education, and lectures for both providers and patients. Paloma is also the Chair of the company’s Diversity, Equity, and Inclusion Council where she leads the company's expungement efforts across the country. Additionally, Dr. Lehfeldt Vice Chairs the National Cannabis Industry Association’s Scientific Advisory Committee. She is passionate about the use of cannabis as medicine and cannabis health equity and looks forward to advocating its healing properties throughout her career.

Disclaimer: There is no conflict of interest or commercial support for this program.

*DCPA Refund Policy:   Refund requests more than one week prior to the webinar should be sent to  If the request comes within one week of the webinar, only credit will be offered.

Our Mission

The D.C. Psychological Association (DCPA) works to advance psychology as a source for the promotion of public welfare and human dignity.

Become a member

Join DCPA as a professional, student, or retired member.
Powered by Wild Apricot Membership Software